Actively Recruiting
Cooperation Between Medical Electroradiology Manipulator and Radiologist in Tumor Imaging Assessments Using RECIST 1.1: CIMER-IPC 2023-030
Led by Institut Paoli-Calmettes · Updated on 2025-03-25
87
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the collaboration between medical electroradiology manipulators (MEMs) and radiologists in interpreting imaging scans for solid cancers using the RECIST 1.1 standard. This observational study aims to assess how MEMs contribute to identifying and measuring cancer lesions, helping to reduce radiologists' workload and enhance report quality. The study focuses on patients already enrolled in oncology protocols requiring RECIST 1.1-based scan evaluations. The study involves a baseline scan interpreted without the radiologist knowing the patient's study status to avoid bias. Then, MEMs conduct a preliminary analysis of the scans, including target and non-target lesions and any new lesions, presenting their findings in a structured format to assist radiologists. This cooperative approach is intended to improve assessment accuracy and speed, with the radiologist validating the MEM's work. The study period lasts up to 24 weeks. Participants will undergo regular imaging evaluations based on their existing cancer protocols. Researchers will assess the quality and accuracy of MEMs' pre-filling work, the benefits to both radiologists and MEMs, and any improvements in clinical research associate processes. Outcomes focus on the detection and measurement of lesions and the overall impact of this collaboration on tumor imaging assessments. Participants' medical follow-up continues as usual throughout the study.
CONDITIONS
Brief Title
Study of Radiology Manipulator Work Validation by the Radiologist
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 and over
- Patient included in a clinical research protocol in oncology for solid cancer including RECIST 1.1 interpretation
- Disease measurable according to RECIST 1.1
- Patient not objecting to study participation
- Member of a social security scheme, or beneficiary of such a scheme
You will not qualify if you...
- Patients with lymphoma or leukemia
- Patient contraindicated to iodinated contrast media injection
- Person in an emergency situation, under legal protection (guardianship, curatorship, or safeguard of justice), or unable to express non-opposition to participate
- Unable to undergo medical follow-up for geographical, social, or psychological reasons
- Patient with renal insufficiency or allergy preventing iodinated contrast injection during the trial
- Patient refusing iodinated contrast injection during the study
- Patient withdrawn from the study including scanner interpretation in RECIST 1.1
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 24 weeks
Participants undergo baseline and follow-up imaging assessments to evaluate tumor status using RECIST 1.1 criteria.
Baseline and evaluation examinations generally every 6 weeks
Trial Site Locations
Total: 1 location
1
Institut PAoli Camettes
Marseille, Institut Paoli Calmettes, France, 13009
Actively Recruiting
Research Team
J
Jihane PAKRADOUNI, Pr
A
Allison Arthur, Mme
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here